<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35543533</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-9537</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Blood advances</Title><ISOAbbreviation>Blood Adv</ISOAbbreviation></Journal><ArticleTitle>Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis.</ArticleTitle><Pagination><StartPage>4041</StartPage><EndPage>4048</EndPage><MedlinePgn>4041-4048</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2021006944</ELocationID><Abstract><AbstractText>Post-COVID syndrome (PCS), or long COVID, is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance, chest pain, shortness of breath, and cognitive slowing. Acute COVID-19 is strongly linked with an increased risk of thrombosis, which is a prothrombotic state quantified by an elevated von Willebrand factor (VWF) antigen (Ag)/ADAMTS13 ratio that is associated with severity of acute COVID-19 infection. We investigated whether patients with PCS also had evidence of a prothrombotic state associated with symptom severity. In a large cohort of patients referred to a dedicated post-COVID-19 clinic, thrombotic risk, including VWF(Ag)/ADAMTS13 ratio, was investigated. An elevated VWF(Ag)/ADAMTS13 ratio (&#x2265;1.5) was present in nearly one-third of the cohort and was 4 times more likely to be present in patients with impaired exercise capacity, as evidenced by desaturation &#x2265;3% and/or an increase in lactate level &gt;1 from baseline on a 1-minute sit-to-stand test and/or a 6-minute walk test (P &lt; .0001). Of 276 patients, 56 (20%) had impaired exercise capacity, of which 55% (31/56) had a VWF(Ag)/ADAMTS13 ratio &#x2265;1.5 (P &lt; .0001). Factor VIII and VWF(Ag) were elevated in 26% and 18%, respectively, and support a hypercoagulable state in some patients with PCS. These findings suggest possible ongoing microvascular/endothelial dysfunction in the pathogenesis of PCS and suggest a role for antithrombotic therapy in the treatment of these patients.</AbstractText><CopyrightInformation>&#xa9; 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prasannan</LastName><ForeName>Nithya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heightman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7507-2119</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillman</LastName><ForeName>Toby</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3711-3960</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2732-4497</Identifier><AffiliationInfo><Affiliation>Biomedical Research Centre, University College London Hospitals (UCLH) NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2199-2638</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Medical Specialities, UCLH London NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neave</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaraj</LastName><ForeName>Akshitha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Special Coagulation, Health Services Laboratories, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehbi</LastName><ForeName>Hakim-Moulay</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Comprehensive Clinical Trials Unit at UCL, London, United Kingdom; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scully</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Haemostasis Research Unit, University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiometabolic Programme National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Adv</MedlineTA><NlmUniqueID>101698425</NlmUniqueID><ISSNLinking>2473-9529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="C099604">ADAMTS13 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017079" MajorTopicYN="N">Exercise Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35543533</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pii">485206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Worldometers. Covid Live Update. 2021. https://www.worldometers.info/coronavirus/. Accessed 21 November 2021.</Citation></Reference><Reference><Citation>COVID-19: Preparing for the future. The Academy of Medical Sciences. 2021. https://acmedsci.ac.uk/publications. Accessed 1 November 2021.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organnization. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 1 November 2021.</Citation></Reference><Reference><Citation>Office of National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7october2021. Accessed 1 November 2021.</Citation></Reference><Reference><Citation>National Institution of Health Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188]. 2020. https://www.nice.org.uk/guidance/ng188. Accessed 11 November 2021.</Citation></Reference><Reference><Citation>Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101-115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305763</ArticleId><ArticleId IdType="pubmed">32788101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I, Baronciani L, Artoni A, et al. . The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19(2):513-521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeeva D, Christian J, Goshua G, Chun H, Lee A, Pine A. VWF/ADAMTS13 ratios are potential markers of immunothrombotic complications in patients with COVID-19: a cross-sectional study. Blood. 2020;136(suppl 1):34-35.</Citation></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. . Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021;5(3):756-759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857699</ArticleId><ArticleId IdType="pubmed">33560386</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T. Persistent endotheliopathy in the pathogenesis of long COVID syndrome: comment from von Meijenfeldt et&#xa0;al. J Thromb Haemost. 2022;20(1):267-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646477</ArticleId><ArticleId IdType="pubmed">34731533</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems LH, Nagy M, Ten Cate H, et al. . Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3&#xa0;months after COVID-19. Thromb Res. 2022;209:106-114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642246</ArticleId><ArticleId IdType="pubmed">34922160</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. . Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol. 2007;136(4):649-655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17367414</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapo R, Casaburi R, Coates A, et al. ; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories . ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetta A, Zanini A, Pisi G, et al. . Reference values for the 6-min walk test in healthy subjects 20-50 years old. Respir Med. 2006;100(9):1573-1578.</Citation><ArticleIdList><ArticleId IdType="pubmed">16466676</ArticleId></ArticleIdList></Reference><Reference><Citation>Reychler G, Boucard E, Peran L, et al. . One minute sit-to-stand test is an alternative to 6MWT to measure functional exercise performance in COPD patients. Clin Respir J. 2018;12(3):1247-1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">28621019</ArticleId></ArticleIdList></Reference><Reference><Citation>Briand J, Behal H, Chenivesse C, W&#xe9;meau-Stervinou L, Wallaert B. The 1-minute sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease. Ther Adv Respir Dis. 2018;12:1753466618793028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088463</ArticleId><ArticleId IdType="pubmed">30091679</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Cort&#xe9;s R, Rivera-Lillo G, Arias-Campoverde M, Soto-Garc&#xed;a D, Garc&#xed;a-Palomera R, Torres-Castro R. Use of sit-to-stand test to assess the physical capacity and exertional desaturation in patients post COVID-19. Chron Respir Dis. 2021;18:1479973121999205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923980</ArticleId><ArticleId IdType="pubmed">33645261</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Updated estimates of the prevalence of long COVID symptoms. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms. Accessed 1 November 2021.</Citation></Reference><Reference><Citation>Heightman M, Prashar J, Hillman TE, et al. . Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. BMJ Open Respir Res. 2021;8(1):e001041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8587466</ArticleId><ArticleId IdType="pubmed">34764200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, et al. ; COVERSCAN study investigators . Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al. . Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. . &#x201c;Long-COVID&#x201d;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76(4):396-398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, et al. ; Irish COVID-19 Vasculopathy Study (iCVS) investigators . Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546-2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>